Company / SG&A per Share
Acadia Pharmaceuticals SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$3.29
FY2025
5-year range
$2.29 / $3.29
FY2021-FY2025
Trend
+11.0%
vs FY2024
Sector context
#55 of 210
Health Care
What the data says
At $3.29, Acadia Pharmaceuticals's sg&a per share ranks #156 of 210 in the Health Care sector. SG&A per Share has increased for 3 consecutive years, from $2.29 in FY2022 to $3.29 in FY2025.
Based on SEC 10-K filings.
3.29 in FY2025 with a 5-year CAGR of +5.6%.
Increased from $2.51 to $3.29 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- +5.6%
- 10-Year CAGR
- -
Sector benchmark
#156 of 210 in Health CareTop 74% of 210This company $3.29 Sector average $29.50
▼
-88.8% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 11.0% year-over-year.
- Ranks #55 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.29 | +11.0% |
| FY2024 | $2.97 | +18.3% |
| FY2023 | $2.51 | +9.4% |
| FY2022 | $2.29 | -7.6% |
| FY2021 | $2.48 | -0.9% |
| FY2020 | $2.50 | +10.6% |
| FY2019 | $2.26 | +6.0% |
| FY2018 | $2.14 | +1.6% |
| FY2017 | $2.10 | +14.9% |
| FY2016 | $1.83 | +107.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026